LJ

Inhaled Insulin: One Giant Leap for MannKind

First of all, inhalable insulin has already been made available to the market by netar. What mannkind is working on is no more than a repetition confusing the investing public. Second, this company has no revenue for many years, and it is no more than a research team surviving on stock sales.

$4.99 is too expensive. In fairness, this stock shouldn't be listed in any proper stock exchange. Instead, it should be listed in pinksheet or OTC.